ESMO Congress 2026
Trine Jakobi Nøttrup, MD, PhD, on BRCA Wild-Type Recurrent Ovarian Cancer: Novel Triplet Maintenance Regimen
Trine Jakobi Nøttrup, MD, PhD, of Rigshospitalet, describes findings from the DOVACC trial, which evaluated the combination of olaparib, durvalumab, and UV1—a therapeutic cancer vaccine directed again...
Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer
Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug c...
Kohei Shitara, MD, on G-HOPE 001: Arcotatug Tavatecan in GI/GEJ Cancer
Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, presents findings from the prespecified first interim analysis of the phase III G-HOPE 001 trial, which showed that ar...
Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the C...
Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pem...
Elizabeth Smyth, MD, on Gastric/GEJ Cancer: Novel CLDN18.2-Targeting ADC
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate a...
Sanjiv S. Gangaram-Panday, PhD, on Esophageal Cancer: Active Surveillance vs Standard Surgery After Neoadjuvant Chemoradiotherapy
Sanjiv S. Gangaram-Panday, PhD, of Erasmus University, presents 5-year outcomes from the Surgery As Needed for Oesophageal Cancer (SANO) trial. The study previously demonstrated that active surveillan...
James J. Harding, MD, on Advanced Biliary Tract Cancer: Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy
The phase III HARMONi-GI1 trial is evaluating the efficacy and safety of ivonescimab, a PD-1/VEGF bispecific antibody, plus chemotherapy vs durvalumab plus chemotherapy as first-line treatment for adv...
Shannon N. Westin, MD, on Advanced or Recurrent Endometrial Cancer: DUO-E/GOG-3041/ENGOT-EN10
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplati...
Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch ...
